By Jennifer Chiou
New York, Oct. 11 - Trigen Holdings AG announced it raised €26.5 million in financing.
Wellington Partners, HealthCap and 3i led investors, which included SR One, Quintiles PharmaBio Development, Quest for Growth, BIT, Merifin and others.
"In addition to being able to progress our lead products in clinical development, this round is an important step in Trigen's corporate development," chief executive officer Sanjay Kakkar said in a news release.
"We have expanded our shareholder base with additional high quality specialist VC, crossover and corporate venture funds."
Proceeds will be used for the clinical development of Trigen's lead products, including TGN 255, an intravenous direct thrombin inhibitor, which will begin a Phase III program in 2006. The company also has TGN 167, an oral direct thrombin inhibitor, which is in Phase I/Ib trials, and PR-15, an anti-platelet agent.
The London-based biopharmaceutical company focuses on cardiovascular drug discovery and development, including thrombosis and vascular dysfunction.
| Issuer: | Trigen Holdings AG
|
| Issue: | Preferred stock
|
| Amount: | €26.5 million
|
| Investors: | Wellington Partners, HealthCap, 3i (co-leads); SR One, Quintiles PharmaBio Development, Quest for Growth, BIT, Merifin, others
|
| Announcement date: | Oct. 11
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
